Oxidative stress–induced mitochondrial dysfunction drives inflammation and airway smooth muscle remodeling in patients with chronic obstructive pulmonary disease

Top Cited Papers
Open Access
Abstract
No abstract available
Funding Information
  • European Commission (093080/Z/10/Z, G1001367/1, 093080/Z/10/Z)
  • Dunhill Medical Trust (093080/Z/10/Z, G1001367/1, 093080/Z/10/Z)
  • AstraZeneca (093080/Z/10/Z, G1001367/1, 093080/Z/10/Z)
  • European Research Council (093080/Z/10/Z, G1001367/1, 093080/Z/10/Z)
  • Boehringer Ingelheim (093080/Z/10/Z, G1001367/1, 093080/Z/10/Z)
  • GlaxoSmithKline (093080/Z/10/Z, G1001367/1, 093080/Z/10/Z)
  • Medical Research Council (093080/Z/10/Z, G1001367/1, 093080/Z/10/Z)
  • Merck Sharp and Dohme (093080/Z/10/Z, G1001367/1, 093080/Z/10/Z)
  • Innovative Medicines Initiative (093080/Z/10/Z, G1001367/1, 093080/Z/10/Z)
  • Wellcome Trust (093080/Z/10/Z, G1001367/1, 093080/Z/10/Z)
  • National Institutes of Health (093080/Z/10/Z, G1001367/1, 093080/Z/10/Z)
  • Imperial College London (093080/Z/10/Z, G1001367/1, 093080/Z/10/Z)
  • Wellcome Trust (093080/Z/10/Z, G1001367/1, 093080/Z/10/Z)
  • Novartis (093080/Z/10/Z, G1001367/1, 093080/Z/10/Z)
  • Royal Brompton and Harefield NHS Foundation Trust (093080/Z/10/Z, G1001367/1, 093080/Z/10/Z)
  • National Institute for Health Research (093080/Z/10/Z, G1001367/1, 093080/Z/10/Z)